New imaging agent could reveal which cancers respond to immunotherapy

NCT ID NCT05888532

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adults with advanced genitourinary cancers like prostate, kidney, or bladder cancer. The main goals are to check safety and see if the tracer can measure immune responses over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
64Cu-GRIP B (a radioactive tracer that targets granzyme B, an immune cell marker)
What this could lead to
If successful, this imaging method could help doctors see which tumors are responding to immunotherapy early on, guiding treatment decisions.
What could go wrong
This is an early-phase trial focused on safety and imaging, not treatment. The tracer may not reliably predict responses, and results may not apply to all cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.